手机APP下载

您现在的位置: 首页 > 在线广播 > VOA慢速英语 > VOA慢速-健康报道 > 正文

VOA慢速英语(翻译+字幕+讲解):礼来公司寻求实验性新冠肺炎抗体药物获批

来源:可可英语 编辑:aimee   VIP免费外教试听课 |  可可官方微信:ikekenet
 下载MP3到电脑  批量下载MP3和LRC到手机
加载中..
IAFvC-rhXX!!dcz*6P

X=_6SlNigo6.

Eli Lilly Seeks Approval for Experimental COVID-19 Antibody Drug
Drug maker Eli Lilly and Company said Wednesday it has asked U.S. officials to approve emergency use of an experimental antibody treatment for COVID-19.
Lilly said early results of a study show the treatment reduced hospital emergency room visits for persons with mild or moderate forms of COVID-19. It said the therapy also reduced signs of the disease, the amount of the virus and length of hospital stays for such patients.
The company announced the study's partial results before a meeting with investors and the public. The findings have yet to be published or examined by independent scientists.
The antibody treatment appears to work like one given to President Donald Trump last Friday. The treatment he took was developed by Regeneron Pharmaceuticals.
Both therapies are designed to connect human antibodies to the coronavirus that causes COVID-19 and limit its ability to spread. The antibodies are usually given as a one-time treatment through intravenous therapy.
Daniel Skovronsky is a doctor and Eli Lilly's chief scientific officer. He said in a statement, "We believe the data generated to date provide sufficient evidence that both monotherapy and combination therapy may be effective to treat COVID-19 in patients with a high risk for serious outcomes."

oN%BJoZRaYtz

礼来新冠药申请紧急使用授权.jpeg
The monotherapy involves an antibody called LY-CoV555. The combination therapy combines that antibody with an antibody called LY-CoV016.
The medical news website StatNews reported that "Lilly had previously released results for a similar treatment using one antibody, which experts viewed as promising. But the new results, of a combination of two antibodies, appear, based on limited data provided in a press release, to be more robust."
The drug maker is asking the U.S. Food and Drug Administration (FDA) to permit use of its single antibody treatment in emergency situations. The company expects to seek government approval of the combination treatment in November.
At this time, the FDA has only approved the drug remdesivir for emergency use in COVID-19 patients. The president's personal doctor confirmed that Trump has also started a five-day treatment of remdesivir.
Lilly said it has already started manufacturing the drug LY-CoV555. The company expects to have 100,000 doses ready in October and 1 million by the end of the year. It hopes to have 50,000 doses of the combination therapy ready by year's end.
The drug maker added that it is also "working with regulators around the world to make these treatments available."
I'm Jonathan Evans.

l4%NkIIcOhyhAOFFOY

iIl!&2z|Z@vJ5zuRU+

#-jOLc=Do8^,Wo6]O1s*HylZ([kuF.eN5|s+*NnsNC6b+LGv

重点单词   查看全部解释    
therapy ['θerəpi]

想一想再看

n. 疗法,治疗

 
limited ['limitid]

想一想再看

adj. 有限的,被限制的
动词limit的过

 
experimental [iks.peri'mentl]

想一想再看

adj. 实验(性)的,试验(性)的

 
announced [ə'naunst]

想一想再看

宣布的

 
sufficient [sə'fiʃənt]

想一想再看

adj. 足够的,充分的

联想记忆
combination [.kɔmbi'neiʃən]

想一想再看

n. 结合,联合,联合体

联想记忆
inaccurate [in'ækjurit]

想一想再看

adj. 不准确的,错误的

 
statement ['steitmənt]

想一想再看

n. 声明,陈述

联想记忆
mild [maild]

想一想再看

adj. 温和的,柔和的

 
approval [ə'pru:vəl]

想一想再看

n. 批准,认可,同意,赞同

联想记忆

发布评论我来说2句

    最新文章

    可可英语官方微信(微信号:ikekenet)

    每天向大家推送短小精悍的英语学习资料.

    添加方式1.扫描上方可可官方微信二维码。
    添加方式2.搜索微信号ikekenet添加即可。